Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process. (3rd November 2021)

• Record Type: Journal Article
• Authors: Rubin, Emily B; Boiarsky, Jonathan A; Canha, Lauren A; Giobbie-Hurder, Anita; Liu, Mofei; Townsend, Matthew J; Dougan, Michael
• Is Part Of: Open forum infectious diseases. Volume 8:Number 12(2021)
• Publication Date: 2021-11-03
• Subjects: COVID-19 -- monoclonal antibodies; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab546
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Given the challenges associated with timely delivery of monoclonal antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most likely to benefit, it is critical to understand the effectiveness of such therapy outside the context of clinical trials. Methods: This was a case–control study of 1257 adult outpatients with COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery for mAb therapy. Results: Patients who were called to be offered mAb therapy had a statistically significant 44% reduction in the odds of hospitalization within 30 days of a positive severe acute respiratory syndrome coronavirus 2 test compared with those who were not called (odds ratio [OR], 0.56; 95% CI, 0.36–0.89; P =.01). Patients who actually received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11–0.93; P =.04). Conclusions: This study supports the effectiveness of bamlanivimab in reducing COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.